logo
explain how to read the page

The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers
Active 6
Ceased 3
  • 1
    Dr. Annelise Juliette Soulier
    Born in May 1979
    Individual (1 offspring)
    Person with significant control
    icon of calendar 2021-01-20 ~ 2024-01-21
    PE - Ownership of voting rights - More than 25% but not more than 50% → CIF 0
    PE - Ownership of shares – More than 25% but not more than 50% → CIF 0
    PE - Right to appoint or remove directors → CIF 0
  • 2
    Dr. Pedro Vaz De Almada Correa De Sampaio
    Born in August 1984
    Individual (1 offspring)
    Person with significant control
    icon of calendar 2021-01-20 ~ 2024-01-21
    PE - Ownership of shares – More than 25% but not more than 50% → CIF 0
    PE - Right to appoint or remove directors → CIF 0
    PE - Ownership of voting rights - More than 25% but not more than 50% → CIF 0
  • 3
    Hammond, Mark William Jonathan Charles, Dr
    Director born in June 1983
    Individual (2 offsprings)
    Officer
    icon of calendar 2021-01-20 ~ 2021-04-14
    OF - Director → CIF 0
parent relation
Company in focus

NEOBE THERAPEUTICS LTD

Standard Industrial Classification
72110 - Research And Experimental Development On Biotechnology
Brief company account
Average Number of Employees
62024-02-01 ~ 2024-12-31
52023-02-01 ~ 2024-01-31
Property, Plant & Equipment
8,673 GBP2024-12-31
6,834 GBP2024-01-31
Fixed Assets
8,673 GBP2024-12-31
6,834 GBP2024-01-31
Debtors
Current
381,563 GBP2024-12-31
137,043 GBP2024-01-31
Cash at bank and in hand
440,326 GBP2024-12-31
1,037,336 GBP2024-01-31
Current Assets
821,889 GBP2024-12-31
1,174,379 GBP2024-01-31
Net Current Assets/Liabilities
684,828 GBP2024-12-31
1,123,886 GBP2024-01-31
Total Assets Less Current Liabilities
693,501 GBP2024-12-31
1,130,720 GBP2024-01-31
Net Assets/Liabilities
693,501 GBP2024-12-31
1,130,720 GBP2024-01-31
Equity
Called up share capital
181 GBP2024-12-31
181 GBP2024-01-31
Share premium
1,520,347 GBP2024-12-31
1,520,347 GBP2024-01-31
Retained earnings (accumulated losses)
-827,027 GBP2024-12-31
-389,808 GBP2024-01-31
Equity
693,501 GBP2024-12-31
1,130,720 GBP2024-01-31
Property, Plant & Equipment - Depreciation rate used
Plant and equipment
252024-02-01 ~ 2024-12-31
Office equipment
252024-02-01 ~ 2024-12-31
Property, Plant & Equipment - Gross Cost
Plant and equipment
10,006 GBP2024-12-31
6,838 GBP2024-01-31
Office equipment
1,130 GBP2024-12-31
412 GBP2024-01-31
Property, Plant & Equipment - Gross Cost
11,136 GBP2024-12-31
7,250 GBP2024-01-31
Property, Plant & Equipment - Accumulated Depreciation (Not Including Impairment)
Plant and equipment
330 GBP2024-01-31
Office equipment
86 GBP2024-01-31
Property, Plant & Equipment - Accumulated Depreciation (Not Including Impairment)
416 GBP2024-01-31
Property, Plant & Equipment - Increase From Depreciation Charge for Year
Owned/Freehold
2,047 GBP2024-02-01 ~ 2024-12-31
Property, Plant & Equipment - Accumulated Depreciation & Impairment
Plant and equipment
2,158 GBP2024-12-31
Office equipment
305 GBP2024-12-31
Property, Plant & Equipment - Accumulated Depreciation & Impairment
2,463 GBP2024-12-31
Property, Plant & Equipment
Plant and equipment
7,848 GBP2024-12-31
6,508 GBP2024-01-31
Office equipment
825 GBP2024-12-31
326 GBP2024-01-31
Other Debtors
Current
189,792 GBP2024-12-31
60,355 GBP2024-01-31
Prepayments/Accrued Income
Current
191,771 GBP2024-12-31
76,688 GBP2024-01-31
Trade Creditors/Trade Payables
Current
120,682 GBP2024-12-31
40,803 GBP2024-01-31
Taxation/Social Security Payable
Current
11,970 GBP2024-12-31
6,917 GBP2024-01-31
Other Creditors
Current
1,559 GBP2024-12-31
1,079 GBP2024-01-31
Accrued Liabilities/Deferred Income
Current
2,850 GBP2024-12-31
1,694 GBP2024-01-31
Creditors
Current
137,061 GBP2024-12-31
50,493 GBP2024-01-31
Number of Shares Issued (Fully Paid)
Class 1 ordinary share
180,611 shares2024-12-31
120,858 shares2024-01-31
Par Value of Share
Class 1 ordinary share
0.0012024-02-01 ~ 2024-12-31
Future Minimum Lease Payments Under Non-cancellable Operating Leases
Amounts falling due within one year
31,686 GBP2024-12-31
17,419 GBP2024-01-31
Between one and five year
8,395 GBP2024-12-31
2,903 GBP2024-01-31
Future Minimum Lease Payments Under Non-cancellable Operating Leases
40,081 GBP2024-12-31
20,322 GBP2024-01-31
  • NEOBE THERAPEUTICS LTD
    Info
    Registered number 13146056
    icon of addressSalisbury House, Station Road, Cambridge CB1 2LA
    PRIVATE LIMITED COMPANY incorporated on 2021-01-20 (5 years). The company status is Active.
    The last date of confirmation statement was made at 2025-01-20
    CIF 0
child relation
Offspring entities and appointments
Active 0
  • Not found in our database.

qrcode

Privacy notice

Terms and conditions

The content of this website is protected by AgonGuard.

© 2022- Polylogarithmic Technology Ltd (Registered in England and Wales No. 14256313). All rights reserved.

Contains public sector information retrieved at 12 November 2025 and licensed under the Open Government Licence v3.0.